登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C96H184N3O22P
化学文摘社编号:
分子量:
1763.47
MDL number:
NACRES:
NA.25
UNSPSC Code:
12352211
产品名称
MPLA (PHAD ™), Avanti Research™ - A Croda Brand
description
Monophosphoryl Lipid A (Synthetic) (PHAD™)
assay
>99% (HPLC)
form
powder
packaging
pkg of 1 × 1 mg (699800P-1mg)
pkg of 1 × 5 mg (699800P-5mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
application(s)
vaccine development
shipped in
dry ice
storage temp.
−20°C
Application
PHAD单磷酰脂质A™已用于：
- 作为钴卟啉-磷脂(Co-PoP)脂质体组分，用于使用gp41包膜蛋白的近膜端外部区(MPER)免疫小鼠
- 与双十八烷基二甲基溴化铵(DDA)共同作为佐剂，用于基于沙眼衣原体重组膜蛋白的多亚单位疫苗
- 用作呼吸道合胞病毒(RSV)融合(F)蛋白FI-RSV疫苗的toll样受体4(TLR4)激动剂佐剂
Biochem/physiol Actions
单磷酰脂质A(MPLA)是toll样受体(TLR4)的天然激动剂。它可用作免疫佐剂。单磷酰脂质A是安全的预防性药物，可用于免疫治疗。在疫苗中使用单磷酰脂质A可提高B细胞和T细胞介导免疫力。
General description
单磷酰脂质A(MPLA)可从细菌类脂A中提取或通过化学法合成。
通过在感染前产生病原体特异性免疫应答，接种疫苗被公认为预防感染的有效方法。通常，单独使用疫苗抗原进行免疫接种并不能够诱导稳健或持久的免疫反应——导致抵抗感染的保护性免疫失败。因此，需要佐剂增强免疫后的细胞或体液免疫应答。由于已证明使用类脂 A 的疫苗佐剂在动物和人疫苗中诱导异源蛋白的 Th-1 类型免疫应答安全有效，Avanti 开发了磷酸化六酰基二糖 (PHAD ™)，这是第一种可用作人疫苗佐剂的全合成单磷酸化类脂 A。
Other Notes
仅供研发使用。不用于药物、家庭或其他用途。
Packaging
2 mL 棕色玻璃钳口盖瓶 (699800P-1 mg)
2 mL 棕色玻璃钳口盖瓶 (699800P-5 mg)
Preparation Note
Soluble in ethanol at 1mg/mL, soluble in DMSO at 5mg/mL, soluble in Chloroform:Methanol:Water at 5mg/mL, insoluble in water (aqueous buffers, serum etc.); however, it can be dispersed in an aqueous medium using a suitable emulsifier or detergent. This species is soluble in chloroform (at least up to 50 mg/mL) and chloroform:methanol solvent systems, however gentle heating and sonication may be necessary to aid in dissolution. Dropwise additions of methanol or water may aid dissolution in chloroform at higher concentrations. If using in combination with other lipids, dissolve this lipid separately and then combine dissolved lipids in their respective solvent solutions.
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
PHAD is a trademark of Avanti Polar Lipids, LLC
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Christopher B Fox et al.
Sub-cellular biochemistry, 53, 303-321 (2010-07-02)
Natural derivatives and synthetic analogues of lipopolysaccharide are potent stimulators of the mammalian immune system. Retained adjuvant activity with reduced toxicity was obtained by the development of monophosphoryl lipid A (MPL((R))), which is approved for use in several vaccine products.
Katharina Richard et al.
Vaccine, 38(27), 4298-4308 (2020-05-12)
Toll-like receptors (TLRs), a family of "pattern recognition receptors," bind microbial and host-derived molecules, leading to intracellular signaling and proinflammatory gene expression. TLR4 is unique in that ligand-mediated activation requires the co-receptor myeloid differentiation 2 (MD2) to initiate two signaling
Rhea N Coler et al.
PloS one, 6(1), e16333-e16333 (2011-02-08)
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I
Susana Lousada-Dietrich et al.
Vaccine, 29(17), 3284-3292 (2011-02-26)
GMZ2 adjuvanted by aluminum hydroxide is a candidate malaria vaccine that has successfully passed phase 1 clinical testing in adult German and Gabonese volunteers and Gabonese children under five. Here we report a preclinical study screening a series of adjuvant
Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens
Shao S, et al.
Nature Chemistry, 7(5), 438-438 (2015)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持